BioPharmos Group goes International. February 2013 BIOPHARMOS: NEW - PowerPoint PPT Presentation

BioPharmos Group goes International. February 2013 BIOPHARMOS: NEW OPPORTUNITIES 1 IN BIOTECHNOLOGY FEB 2012

BioPharmos Group Business Area R&D Peptide Synthesis Biotechnological Growth of Rare Plants BioPharmos Group goes International 2

BioPharmos Group: 25+ years in the biotechnology 2012 170% sales growth a 2011 year. Pharmbiotech Oy, Finland 30% sales established growth a 2008 year. Primary Naturals LLC, Headquarter USA renamed to established 1995 BioPharmos LTD, St. Petersburg, First Russia Laureat biotechnolo- Grand Prix 1987 gical product Europeen – Vitagmal – de Qualite, manufacture Geneva Life Science start Business of BioPharmos Group established BioPharmos Group goes International 3

Who are our customers? BioPharmos Group goes International 4

Why BioPharmos Group products? Own patented biotechnology allows:  to grow biomass of rare plants in industrial scale  to receive high quality material in shorter period of time  to suggest products for different industries  to provide raw materials with unique features on customers’ demand BioPharmos Group goes International 5

Plants biomass growth in bioreactors BioPharmos Group goes International 6

BioPharmos Group goes International 7

BioPharmos Group biotechnology in use Vitagmal - biomass extract  of a subtropical medicinal plant Polyscias filicifolia Superior to Ginseng extract  in 12 pharmacological parameters Has the property to reduce  the risk of inborn anomalies (RF patent № 2058786) Included in the Russian  official recommendations for the prevention of pregnancy complications BioPharmos Group goes International 8

Why to expand production?  9 large-scale pharmaceuticals projects in Saint- Petersburg and region with 25.12 billion rub. investment volume started in 2010 (Pharma 2020 Program)  Tough competition makes pharmaceuticals producers to search for raw materials with unique features  Biotech companies market supply is limited BioPharmos Group goes International 9

Why production in Finland?  Economic situation predictability  Innovative industries support on state and local levels  Russian investments state support program  High level of Finnish management  Territorial proximity  Confidence in quality of Finnish products BioPharmos Group goes International 10

Thank you for your time Oleg Kotin BioPharmos Group Chairman of the Board of Directors E-mail: okotin@pharmbiotech.eu Phone: +358 44 920 0207 www.pharmbiotech.eu